Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Hudson

Dermatology Evansville, IN Medical Doctor

NPI 1356393102 CMS profile 60996

3501 Washington Ave, Evansville, IN 47714

Open in the dashboard

General payments

$91,623

280 records reported · program years 2019–2025

Research payments

$4,469

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$497,244 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Charles Hudson of Evansville, IN is reported in the CMS Open Payments database as having received $91,623 across 280 general payments and $4,469 in research payments paid to them. Separately, studies naming them as principal investigator received $497,244 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $198 3
2024 General $255 4
2023 General $591 12
2022 General $766 26
2021 General $10,519 49
2020 General $26,671 66
2020 Research $22 1
2019 General $52,625 120
2019 Research $4,447 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Hudson
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Charles Hudson were reported at $198. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Charles Hudson Dermatology median Middle half National median
2019 $52,625 $454 $129–$1,240 $163
2020 $26,671 $235 $81–$756 $114
2021 $10,519 $377 $108–$1,108 $132
2022 $766 $514 $143–$1,391 $149
2023 $591 $607 $159–$1,674 $160
2024 $255 $751 $204–$1,903 $164
2025 $198 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $77,850 140 payments
  2. VYNE Pharmaceuticals Inc. $8,694 13 payments
  3. Merz North America, Inc. $1,146 18 payments
  4. Almirall LLC $800 1 payment
  5. Lilly USA, LLC $463 14 payments
  6. Novartis Pharmaceuticals Corporation $362 11 payments
  7. Sun Pharmaceutical Industries Inc. $342 8 payments
  8. Janssen Biotech, Inc. $237 16 payments
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $210 9 payments
  10. EPI Health, LLC $204 12 payments
  11. Other $1,315 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $66,700 29 payments
  2. Travel and Lodging $9,789 36 payments
  3. Food and Beverage $7,241 207 payments
  4. Honoraria $7,000 3 payments
  5. Consulting Fee $800 1 payment
  6. Education $93 4 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $40,078 59 payments
  2. SKYRIZI $16,881 49 payments
  3. AMZEEQ $8,670 11 payments
  4. Seysara $800 1 payment
  5. Xeomin Dermatology $370 4 payments
  6. TALTZ $365 13 payments
  7. Xeomin musculoskeletal $295 4 payments
  8. Winlevi $279 4 payments
  9. COSENTYX $223 5 payments
  10. ASCLERA $217 2 payments
  11. Other $3,646 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $4,469 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

108

Median for Dermatology: 534

Drug cost

$74,514

Median for Dermatology: $67,151

Branded share of claims

77.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 15 $66,526
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $6,980
Valacyclovir Valacyclovir Hcl Brand 33 $651
Minocycline Hcl Generic 24 $270
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 13 $47
Losartan-Hydrochlorothiazide Losartan/Hydrochlorothiazide Brand 11 $41

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Bimzelx
  • UCB, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

283 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record